Mystic Pharmaceuticals Unveils The Next Generation Of Patient-Centric Sublingual Drug Delivery Devices
7/15/2014 9:37:50 AM
AUSTIN, Texas--(BUSINESS WIRE)--Mystic Pharmaceuticals, Inc. today announced the availability of its Javelin Sublingual™ drug delivery devices. Javelin Sublingual dispensers utilized Mystic’s VersiDoser® and VRx2™ platform technology, and are offered in mono-dose and multi-dose configurations. Sublingual and buccal delivery provides non-invasive, delivery of drugs, peptides, proteins and enzymes through mucosal surfaces in the oral cavity. This route avoids first pass metabolism, provides rapid systemic uptake into the body and can be self-administered by the patient. Applications include the delivery of therapeutics for pain, cardiovascular, allergy, seizure, sedation, emesis, hormones, diabetes and vaccines.
Help employers find you! Check out all the jobs and post your resume.
comments powered by